Journal Article

PreJuSER-7089

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Fluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences

Coenen, H. H.FZJ* ; Elsinga, P. H. ; Iwata, R. ; Kilbourn, M. R. ; Pillai, M. R. A. ; Rajan, M. G. R. ; Wagner, H. N. ; Zaknun, J.

2010
Elsevier Amsterdam [u.a.]

This record in other databases:      

Please use a persistent id in citations: doi:10.1016/j.nucmedbio.2010.04.185

Abstract: Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ((18)F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the (18)F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful (18)F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of (18)F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of (18)F-tracers for oncology and neurosciences. A selection of three groups of (18)F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on "Development of (18)F radiopharmaceuticals (beyond [(18)F]FDG) for use in oncology and neurosciences" in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more (18)F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences.

Keyword(s): Animals (MeSH) ; Fluorodeoxyglucose F18: diagnostic use (MeSH) ; Humans (MeSH) ; Neoplasms: radionuclide imaging (MeSH) ; Nervous System Diseases: radionuclide imaging (MeSH) ; Radiopharmaceuticals: diagnostic use (MeSH) ; Radiopharmaceuticals ; Fluorodeoxyglucose F18 ; J

Note: The Consultants acknowledge the IAEA for its interest and activities in this important field. The authors from the IAEA (MRAP and JJZ) thank Dr. M. Haji-Saeid, Head, Industrial Applications and Chemistry Section, Dr. M. Dondi, Head, Nuclear Medicine Section, and Dr N. Ramamoorthy, Director-NAPC, International Atomic Energy Agency for their support and encouragement.

---

Contributing Institute(s):

1. Nuklearchemie (INM-5)
2. Jülich-Aachen Research Alliance - Translational Brain Medicine (JARA-BRAIN)

Research Program(s):

1. Funktion und Dysfunktion des Nervensystems (FUEK409) (FUEK409)
2. 89572 - (Dys-)function and Plasticity (POF2-89572) (POF2-89572)

Appears in the scientific report 2010

---